Search
tezacaftor
Indications:
- cystic fibrosis in combination with ivacaftor [1,2]
Dosage:
- 100 mg QD [1]
Mechanism of action:
- CFTR potentiator (presumably)
General
pulmonary agent
heterocyclic compound, 2 rings
amide
Database Correlations
PUBCHEM cid=46199646
References
- Taylor-Cousar JL, Munck A, McKone EF et al
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis
Homozygous for Phe508del.
N Engl J Med 2017; 377:2013-2023. Nov 23, 2017
PMID: 29099344 Free full text
http://www.nejm.org/doi/full/10.1056/NEJMoa1709846
- Rowe SM, Daines C, Ringshausen FC et al
Tezacaftor-Ivacaftor in Residual-Function Heterozygotes
with Cystic Fibrosis.
N Engl J Med 2017; 377:2024-2035. Nov 23, 2017
PMID: 29099333 Free full text
http://www.nejm.org/doi/full/10.1056/NEJMoa1709847
Component-of
elexacaftor/ivacaftor/tezacaftor
ivacaftor/tezacaftor